| Voriconazole treatment for less-common, emerging, or refractory fungal infections JR Perfect, KA Marr, TJ Walsh, RN Greenberg, B DuPont, ... Clinical Infectious Diseases 36 (9), 1122-1131, 2003 | 825 | 2003 |
| Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children TJ Walsh, I Lutsar, T Driscoll, B Dupont, M Roden, P Ghahramani, ... The Pediatric infectious disease journal 21 (3), 240-248, 2002 | 534 | 2002 |
| Improved outcome in central nervous system aspergillosis, using voriconazole treatment S Schwartz, M Ruhnke, P Ribaud, L Corey, T Driscoll, OA Cornely, ... Blood 106 (8), 2641-2645, 2005 | 487 | 2005 |
| Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration TJ Walsh, MO Karlsson, T Driscoll, AG Arguedas, P Adamson, ... Antimicrobial agents and chemotherapy 48 (6), 2166-2172, 2004 | 413 | 2004 |
| Infections Due to Aspergillus terreus: A Multicenter Retrospective Analysis of 83 Cases WJ Steinbach, DK Benjamin Jr, DP Kontoyiannis, JR Perfect, I Lutsar, ... Clinical Infectious Diseases 39 (2), 192-198, 2004 | 350 | 2004 |
| Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients I Lutsar, S Roffey, P Troke Clinical Infectious Diseases 37 (5), 728-732, 2003 | 320 | 2003 |
| Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients P Troke, K Aguirrebengoa, C Arteaga, D Ellis, CH Heath, I Lutsar, ... Antimicrobial agents and chemotherapy 52 (5), 1743-1750, 2008 | 319 | 2008 |
| Antibiotic pharmacodynamics in cerebrospinal fluid I Lutsar, GH McCracken Jr, IR Friedland Clinical Infectious Diseases, 1117-1127, 1998 | 290 | 1998 |
| Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient-and sequence-level meta-analysis SY Rhee, JL Blanco, MR Jordan, J Taylor, P Lemey, V Varghese, ... PLoS medicine 12 (4), e1001810, 2015 | 284 | 2015 |
| Discovery and development of safe-in-man broad-spectrum antiviral agents PI Andersen, A Ianevski, H Lysvand, A Vitkauskiene, V Oksenych, ... International Journal of Infectious Diseases 93, 268-276, 2020 | 271 | 2020 |
| Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies MO Karlsson, I Lutsar, PA Milligan Antimicrobial agents and chemotherapy 53 (3), 935-944, 2009 | 263 | 2009 |
| EAN consensus review on prevention, diagnosis and management of tick‐borne encephalitis P Taba, E Schmutzhard, P Forsberg, I Lutsar, U Ljøstad, Å Mygland, ... European journal of neurology 24 (10), 1214-e61, 2017 | 254 | 2017 |
| Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat? S Esposito, R Cohen, JD Domingo, OF Pecurariu, D Greenberg, ... The Pediatric infectious disease journal 31 (6), e78-85, 2012 | 174 | 2012 |
| Pertussis prevention: reasons for resurgence, and differences in the current acellular pertussis vaccines S Esposito, P Stefanelli, NK Fry, G Fedele, Q He, P Paterson, T Tan, ... Frontiers in immunology 10, 1344, 2019 | 173 | 2019 |
| Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children TJ Walsh, T Driscoll, PA Milligan, ND Wood, H Schlamm, AH Groll, H Jafri, ... Antimicrobial agents and chemotherapy 54 (10), 4116-4123, 2010 | 168 | 2010 |
| Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts G Touloumi, N Pantazis, D Pillay, D Paraskevis, ML Chaix, HC Bucher, ... Clinical infectious diseases 56 (6), 888-897, 2013 | 148 | 2013 |
| Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases H Mouas, I Lutsar, B Dupont, O Fain, R Herbrecht, FX Lescure, ... Clinical infectious diseases 40 (8), 1141-1147, 2005 | 141 | 2005 |
| Low temperature and low UV indexes correlated with peaks of influenza virus activity in Northern Europe during 2010–2018 A Ianevski, E Zusinaite, N Shtaida, H Kallio-Kokko, M Valkonen, A Kantele, ... Viruses 11 (3), 207, 2019 | 123 | 2019 |
| Drug utilisation pattern and off-label use of medicines in Estonian neonatal units J Lass, R Käär, K Jõgi, H Varendi, T Metsvaht, I Lutsar European journal of clinical pharmacology 67, 1263-1271, 2011 | 114 | 2011 |
| Pharmacodynamics of vancomycin for the treatment of experimental penicillin-and cephalosporin-resistant pneumococcal meningitis A Ahmed, H Jafri, I Lutsar, CC McCoig, M Trujillo, L Wubbel, S Shelton, ... Antimicrobial agents and chemotherapy 43 (4), 876-881, 1999 | 113 | 1999 |
Hiie SoeorgEmail confirmado em ut.ee
